Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.74
NAS:IPCI's Cash-to-Debt is ranked lower than
68% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. NAS:IPCI: 2.74 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:IPCI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.35  Med: 5081.78 Max: No Debt
Current: 2.74
Equity-to-Asset 0.14
NAS:IPCI's Equity-to-Asset is ranked lower than
88% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NAS:IPCI: 0.14 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:IPCI' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.36  Med: 0.38 Max: 0.97
Current: 0.14
-1.36
0.97
Piotroski F-Score: 3
Altman Z-Score: -8.42
Beneish M-Score: -4.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -439.39
NAS:IPCI's Operating Margin % is ranked lower than
69% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. NAS:IPCI: -439.39 )
Ranked among companies with meaningful Operating Margin % only.
NAS:IPCI' s Operating Margin % Range Over the Past 10 Years
Min: -9455.14  Med: -438.41 Max: -40.29
Current: -439.39
-9455.14
-40.29
Net Margin % -452.28
NAS:IPCI's Net Margin % is ranked lower than
69% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. NAS:IPCI: -452.28 )
Ranked among companies with meaningful Net Margin % only.
NAS:IPCI' s Net Margin % Range Over the Past 10 Years
Min: -5735.51  Med: -451.45 Max: -43.97
Current: -452.28
-5735.51
-43.97
ROA % -193.97
NAS:IPCI's ROA % is ranked lower than
92% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:IPCI: -193.97 )
Ranked among companies with meaningful ROA % only.
NAS:IPCI' s ROA % Range Over the Past 10 Years
Min: -341.43  Med: -102.99 Max: -64.64
Current: -193.97
-341.43
-64.64
ROC (Joel Greenblatt) % -570.63
NAS:IPCI's ROC (Joel Greenblatt) % is ranked lower than
52% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. NAS:IPCI: -570.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:IPCI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7954.63  Med: -544.16 Max: -235.67
Current: -570.63
-7954.63
-235.67
3-Year Revenue Growth Rate 11.70
NAS:IPCI's 3-Year Revenue Growth Rate is ranked higher than
62% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. NAS:IPCI: 11.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:IPCI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 236.7
Current: 11.7
0
236.7
3-Year EBITDA Growth Rate -5.70
NAS:IPCI's 3-Year EBITDA Growth Rate is ranked lower than
56% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. NAS:IPCI: -5.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:IPCI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.7 Max: 44.9
Current: -5.7
0
44.9
3-Year EPS without NRI Growth Rate -5.70
NAS:IPCI's 3-Year EPS without NRI Growth Rate is ranked lower than
54% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:IPCI: -5.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:IPCI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.45 Max: 63.9
Current: -5.7
0
63.9
GuruFocus has detected 4 Warning Signs with IntelliPharmaCeutics International Inc $NAS:IPCI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:IPCI's 10-Y Financials

Financials (Next Earnings Date: 2017-07-13 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with IPCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare:NAS:AXSM, AMEX:CRMD, OTCPK:AAVXF, NAS:BLRX, NAS:TTNP, OTCPK:AMEUF, OTCPK:CNNRF, NAS:CAPR, NAS:FLKS, NAS:ONS, NAS:TCON, NAS:KALV, NAS:BCLI, OTCPK:BBLG, NAS:RGLS, NAS:SRRA, NAS:PULM, NAS:ALDX, NAS:AKTX, NAS:ADMA » details
Traded in other countries:IPCI.Canada, I4A.Germany,
IntelliPharmaCeutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.

IntelliPharmaCeutics International Inc was incorporated under the Canada Business Corporations Act by certificate and articles of arrangement dated October 22, 2009. The Company a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, it has developed several drug delivery systems and a pipeline of products and product candidates in various stages of development, including ANDAs filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix technologies are applied to the development of both existing and new pharmaceuticals across a range of therapeutic classes. Its scientists have developed drug delivery technology systems, based on the Hypermatrix platform, that facilitate controlled-release delivery of a wide range of pharmaceuticals. These systems include several core technologies, which enable them to flexibly respond to a wide range of drug attributes and patient requirements, producing a desired controlled-release effect. The platform of Hypermatrix drug delivery technologies include, but are not limited to, IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle and nPODDDS. The Company's competitors include medical technology, pharmaceutical, biotechnology and other companies, universities and research institutions. The sales of its products by its licensees outside the United States and Canada will be subject to regulatory requirements governing the testing, registration and marketing of pharmaceuticals, which vary widely from country to country.

Ratios

vs
industry
vs
history
Forward PE Ratio 34.48
IPCI's Forward PE Ratio is ranked lower than
71% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 20.12 vs. IPCI: 34.48 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 70.91
IPCI's PB Ratio is ranked lower than
99% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. IPCI: 70.91 )
Ranked among companies with meaningful PB Ratio only.
IPCI' s PB Ratio Range Over the Past 10 Years
Min: 6.86  Med: 15.66 Max: 551.11
Current: 70.91
6.86
551.11
PS Ratio 30.84
IPCI's PS Ratio is ranked lower than
65% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. IPCI: 30.84 )
Ranked among companies with meaningful PS Ratio only.
IPCI' s PS Ratio Range Over the Past 10 Years
Min: 6  Med: 23.37 Max: 4290
Current: 30.84
6
4290
Current Ratio 1.36
IPCI's Current Ratio is ranked lower than
82% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. IPCI: 1.36 )
Ranked among companies with meaningful Current Ratio only.
IPCI' s Current Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.12 Max: 23.75
Current: 1.36
0.42
23.75
Quick Ratio 1.36
IPCI's Quick Ratio is ranked lower than
78% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. IPCI: 1.36 )
Ranked among companies with meaningful Quick Ratio only.
IPCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.02 Max: 23.75
Current: 1.36
0.42
23.75
Days Sales Outstanding 77.46
IPCI's Days Sales Outstanding is ranked lower than
61% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. IPCI: 77.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.5  Med: 42.08 Max: 352.81
Current: 77.46
0.5
352.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.60
IPCI's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. IPCI: -11.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IPCI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -120.7  Med: -19.9 Max: -10.6
Current: -11.6
-120.7
-10.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 65.00
IPCI's Price-to-Tangible-Book is ranked lower than
98% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. IPCI: 65.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IPCI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.02  Med: 0.53 Max: 286.67
Current: 65
0.02
286.67
Price-to-Median-PS-Value 1.32
IPCI's Price-to-Median-PS-Value is ranked lower than
61% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. IPCI: 1.32 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IPCI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 1.77 Max: 224.29
Current: 1.32
0.34
224.29
Earnings Yield (Greenblatt) % -12.76
IPCI's Earnings Yield (Greenblatt) % is ranked lower than
64% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. IPCI: -12.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IPCI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -671.7  Med: 0 Max: 0
Current: -12.76
-671.7
0

More Statistics

Revenue (TTM) (Mil) $2.25
EPS (TTM) $ -0.38
Beta0.92
Short Percentage of Float8.35%
52-Week Range $1.41 - 3.35
Shares Outstanding (Mil)30.16

Analyst Estimate

Nov17 Nov18 Nov19
Revenue (Mil $) 21 34 104
EPS ($) 0.07 0.27 1.67
EPS without NRI ($) 0.07 0.27 1.67
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IPCI

Headlines

Articles On GuruFocus.com
Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals Feb 04 2015 

More From Other Websites
Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: 2016 By the Numbers : March... Mar 22 2017
Nektar Pharma Opioid Drug Shows Promise In Phase 3 Mar 20 2017
Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI” Mar 16 2017
INTELLIPHARMACEUTICS INTERNATIONAL INC. Financials Mar 07 2017
Monday Movers In Biotech: Cempra Inc (CEMP) And IntelliPharmaCeutics Intl Inc (USA) (IPCI) Feb 27 2017
Biotech's Rise Shows No Sign of Slowing Down in 2017: Today's Reports on IntelliPharmaCeutics and... Feb 27 2017
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR Feb 24 2017
Intellipharmaceutics Announces 2016 Year End Results Feb 10 2017
Intellipharmaceutics Painkiller Qualifies for FDA Review Feb 03 2017
Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone... Feb 02 2017
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par... Jan 06 2017
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par... Jan 06 2017
Intellipharmaceutics to Present at the Biotech Showcase™ Dec 29 2016
Intellipharmaceutics to Present at the Biotech Showcase™ Dec 29 2016
Intellipharmaceutics Announces Issuance of U.S. and Canadian Patents Covering Aspects of its... Dec 21 2016
IntelliPharmaCeutics Intl Inc (USA) (IPCI) Needs A Partner Nov 28 2016
Intellipharmaceutics Submits NDA for Pain Treatment Rexista Nov 28 2016
IntelliPharmaCeutics (IPCI) Jumps: Stock Adds 5% in Session Nov 28 2016
The FDA's Historic Caution On Abuse Deterrent Labeling Nov 25 2016
Raging Bull Portfolio: Abeona Therapeutics Inc (ABEO) And IntelliPharmaCeutics Intl Inc (USA) (IPCI) Nov 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)